Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Safety and Monitoring of the treatment with Disease-Modifying Therapies for Multiple Sclerosis
Curr Rev Clin Exp Pharmacol. 2022 Apr 12. doi: 10.2174/2772432817666220412110720. Online ahead of print.ABSTRACTBACKGROUND: Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS) are widely used given their proven efficacy in the relapsing form of the disease, while recently Siponimod and Ocrelizumab have been approved for the progressive forms of the disease. Currently, 22 Disease-modifying drugs are approved by the FDA, while in 2012, only nine were in the market. From March 2019 until August 2020, six new drugs were approved. This rapid development of new DMTs highlights the need to update our knowledge about th...
Source: Pharmacological Reviews - April 14, 2022 Category: Drugs & Pharmacology Authors: Vasileios-Periklis Stamatellos Georgios Papazisis Source Type: research
Safety and Monitoring of the treatment with Disease-Modifying Therapies for Multiple Sclerosis
Curr Rev Clin Exp Pharmacol. 2022 Apr 12. doi: 10.2174/2772432817666220412110720. Online ahead of print.ABSTRACTBACKGROUND: Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS) are widely used given their proven efficacy in the relapsing form of the disease, while recently Siponimod and Ocrelizumab have been approved for the progressive forms of the disease. Currently, 22 Disease-modifying drugs are approved by the FDA, while in 2012, only nine were in the market. From March 2019 until August 2020, six new drugs were approved. This rapid development of new DMTs highlights the need to update our knowledge about th...
Source: Pharmacological Reviews - April 14, 2022 Category: Drugs & Pharmacology Authors: Vasileios-Periklis Stamatellos Georgios Papazisis Source Type: research
Safety and Monitoring of the treatment with Disease-Modifying Therapies for Multiple Sclerosis
Curr Rev Clin Exp Pharmacol. 2022 Apr 12. doi: 10.2174/2772432817666220412110720. Online ahead of print.ABSTRACTBACKGROUND: Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS) are widely used given their proven efficacy in the relapsing form of the disease, while recently Siponimod and Ocrelizumab have been approved for the progressive forms of the disease. Currently, 22 Disease-modifying drugs are approved by the FDA, while in 2012, only nine were in the market. From March 2019 until August 2020, six new drugs were approved. This rapid development of new DMTs highlights the need to update our knowledge about th...
Source: Pharmacological Reviews - April 14, 2022 Category: Drugs & Pharmacology Authors: Vasileios-Periklis Stamatellos Georgios Papazisis Source Type: research
